PARP1 and neoplasm: Thus, in addition to explore the in-depth drug resistance mechanism of existing inhibitors, as well as the relationship between PARP-mediated signaling pathways and tumor specificity, developing a new type PARP inhibitor with improved therapeutic efficacy and lower toxicity is alternatively promising strategy for TNBC therapy.